Management of Peroneal Vein Thrombosis with Temporal Cavernous Malformation

Introduction to Guideline Recommendations

The American College of Chest Physicians recommends against apixaban use in patients with a temporal cavernous malformation due to the high risk of intracranial hemorrhage, with a baseline annual hemorrhage risk of 0.25-3% per lesion per year, which increases dramatically with anticoagulation 1, 2
The American College of Chest Physicians strongly recommends apixaban as first-line therapy for standard DVT of the leg, but notes that peroneal vein thrombosis has different risk-benefit considerations than proximal DVT 1, 2

For patients with acute proximal DVT and a contraindication to anticoagulation, the American College of Chest Physicians strongly recommends IVC filter placement, with a strong recommendation and moderate-certainty evidence 1, 2
Serial ultrasound surveillance every 1-2 weeks without anticoagulation may be reasonable for isolated distal DVT, as it has a lower risk of PE than proximal DVT 1
IVC filter placement is indicated for proximal extension or high-risk features, given the absolute contraindication to anticoagulation, with a strong recommendation and moderate-certainty evidence 1, 2

Apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily would be the preferred agent if the cavernous malformation is successfully resected or treated, with a strong recommendation and moderate-certainty evidence 1, 5
Reduced-dose apixaban is not recommended due to significant bleeding risk with intracranial vascular malformations 3

Apixaban is 27% renally cleared and should be avoided in severe renal impairment, with a CrCl <15 mL/min 4, 5
Catheter-directed thrombus removal may be considered over systemic anticoagulation if the patient develops PE despite conservative management, in centers with appropriate expertise 1, 2